Cost-Effectiveness of Caplacizumab without First-Line Therapeutic Plasma Exchange Vs. Standard-of-Care for Patients with Immune Thrombotic Thrombocytopenic Purpura: Setting Future Clinical Trial ThresholdsButt A, Lee A, Goshua G. Cost-Effectiveness of Caplacizumab without First-Line Therapeutic Plasma Exchange Vs. Standard-of-Care for Patients with Immune Thrombotic Thrombocytopenic Purpura: Setting Future Clinical Trial Thresholds Blood 2022, 140: 1621-1622. DOI: 10.1182/blood-2022-170003.
COVID-19 and antiphospholipid antibodiesButt A, Erkan D, Lee A. COVID-19 and antiphospholipid antibodies Best Practice & Research Clinical Haematology 2022, 101402. PMCID: PMC9568270, DOI: 10.1016/j.beha.2022.101402.
Association of iron infusion reactions with ABO blood typeButt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.
Iron Infusion Reactions: Risk Factors and Real-World ExperienceButt A, Muradashvili T, Soliman S, Goshua G, Burns A, Bar N, Martin K, Borgman G, Bona R, Lee A, Neparidze N. Iron Infusion Reactions: Risk Factors and Real-World Experience Blood 2021, 138: 4154-4154. DOI: 10.1182/blood-2021-151048.
Transplant in aplastic anemia using combined G-CSF primed blood and bone marrow stem cells – a retrospective analysisAli N, Butt A, Altaf B, Adil S, Shaikh U. Transplant in aplastic anemia using combined G-CSF primed blood and bone marrow stem cells – a retrospective analysis Hematology Transfusion And Cell Therapy 2020, 42: 63. DOI: 10.1016/j.htct.2020.09.113.
Concomitant essential thrombocythemia and mature B-lymphoproliferative disorder in a patientButt A, Qudus R, Ali N. Concomitant essential thrombocythemia and mature B-lymphoproliferative disorder in a patient Hematology Transfusion And Cell Therapy 2020, 42: 41-42. DOI: 10.1016/j.htct.2020.09.074.
PP-96 Outcomes of a newly formed multidisciplinary retinoblastoma serviceButt A, Jeeva I, Masud S, Fadoo Z. PP-96 Outcomes of a newly formed multidisciplinary retinoblastoma service Leukemia Research 2019, 85: s74. DOI: 10.1016/s0145-2126(19)30392-3.
PP-97 Orbital tumor board: life saver or time waster?Butt A, Jeeva I, Masud S, Fadoo Z, Altaf S, Mushtaq N. PP-97 Orbital tumor board: life saver or time waster? Leukemia Research 2019, 85: s74-s75. DOI: 10.1016/s0145-2126(19)30393-5.
PP-39 Idiopathic pulmonary hemosiderosis: a rare cause of chronic anemiaButt A, Ahmed R, Iqbal N, Khan J, Rahman A. PP-39 Idiopathic pulmonary hemosiderosis: a rare cause of chronic anemia Leukemia Research 2019, 85: s54. DOI: 10.1016/s0145-2126(19)30334-0.